Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors

Abstract

Aim: This study aims to investigate the biological role of the proteasome-associated deubiquitinase ubiquitin-specific protease 14 (USP14) in ovarian carcinoma drug resistance and to identify novel USP14 inhibitors (USP14i) for further preclinical development.

Methods: USP14 expression was evaluated in clinical samples from 134 ovarian carcinoma patients and in a broad panel of human ovarian carcinoma cell lines. Functional studies, including gain- and loss-of-function assays, migration and invasion, and apoptosis induction assays, were conducted using cisplatin-sensitive IGROV-1 cells and their cisplatin-resistant derivative IGROV-1/Pt1. A library of 1,056 small molecules was screened using an optimized hydrolysis assay. Docking and molecular dynamics simulations were employed to predict binding modes of candidate inhibitors within the USP14 domain.

Results: In clinical specimens, USP14 mRNA expression was associated with tumor grade. Exogenous overexpression of USP14 enhanced the survival of cisplatin-resistant IGROV-1/Pt1 cells, but not parental IGROV-1 cells, upon cisplatin exposure. USP14 knockdown by small interfering RNAs in resistant cells reduced aggressive features and restored cisplatin sensitivity, whereas no sensitization was observed in IGROV-1 cells. Medium-throughput screening identified five candidate molecules, among which ARN12502 showed the strongest inhibitory activity against USP14. ARN12502 exhibited an IC₅₀ of 18.4 µM, and molecular dynamics simulations confirmed stable binding in two distinct modes. In proteasome sensor-expressing cells, ARN12502 displayed proteasome-inhibitory activity.

Conclusion: USP14 contributes to the aggressiveness of ovarian carcinoma, particularly to the cisplatin-resistant phenotype, and represents a relevant promising druggable target. ARN12502 serves as a starting point for chemical optimization toward the development of more potent USP14i.

Keywords

Deubiquitinases / cisplatin / drug resistance / proteasome

References

[1] Komander D,Urbé S.Breaking the chains: structure and function of the deubiquitinases.Nat Rev Mol Cell Biol2009;10:550-63

[2] Mofers A,Linder S.Proteasome-associated deubiquitinases and cancer.Cancer Metast Rev2017;36:635-53 PMCID:PMC5721125

[3] Harrigan JA,Martin NM.Deubiquitylating enzymes and drug discovery: emerging opportunities.Nat Rev Drug Discov2018;17:57-78 PMCID:PMC7097658

[4] Schauer NJ,Liu X,Buhrlage SJ.Advances in discovering deubiquitinating enzyme (DUB) inhibitors.J Med Chem2020;63:2731-50

[5] Dewson G,Komander D.Deubiquitinases in cancer.Nat Rev Cancer2023;23:842-62

[6] Liu B,Chen M.Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases.Mol Psychiatry2022;27:259-68

[7] Pozhidaeva A.USP7: structure, substrate specificity, and inhibition.DNA Repair2019;76:30-9 PMCID:PMC6481172

[8] Li M,Kon N.A dynamic role of HAUSP in the p53-Mdm2 pathway.Mol Cell2004;13:879-86

[9] Corno C,Bagnoli M.The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosis.Front Cell Dev Biol2022;10:1055067 PMCID:PMC9791127

[10] Colombo D,Sjöstrand L.Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.Biochem Pharmacol2022;197:114900

[11] Beretta GL,Mirra L,Perego P.Deubiquitinases in ovarian cancer: role in drug resistance and tumor aggressiveness.Int J Biol Sci2024;20:5208-22 PMCID:PMC11489175

[12] Konstantinopoulos PA.Clinical and translational advances in ovarian cancer therapy.Nat Cancer2023;4:1239-57

[13] Rottenberg S,Perego P.The rediscovery of platinum-based cancer therapy.Nat Rev Cancer2021;21:37-50

[14] Gatti L,Zaffaroni N,Perego P.New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants.Drug Resist Updat2015;20:1-11

[15] Kane RC,Farrell AT.Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.Oncologist2003;8:508-13

[16] D’Arcy P.Proteasome deubiquitinases as novel targets for cancer therapy.Int J Biochem Cell Biol2012;44:1729-38

[17] Zhang N,Yang X.USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis.BMC Cancer2024;24:237 PMCID:PMC10880281

[18] Liu C,Tang W.USP14 promotes the cancer stem-like cell properties of OSCC via promoting SOX2 deubiquitination.Oral Dis2024;30:4255-65

[19] Zhang S,Yin D.USP14-regulated allostery of the human proteasome by time-resolved cryo-EM.Nature2022;605:567-74 PMCID:PMC9117149

[20] Kim HT.UBL domain of Usp14 and other proteins stimulates proteasome activities and protein degradation in cells.Proc Natl Acad Sci U S A2018;115:E11642-50 PMCID:PMC6294929

[21] D’Arcy P,Olofsson MH.Inhibition of proteasome deubiquitinating activity as a new cancer therapy.Nat Med2011;17:1636-40

[22] Wang X,Caulfield TR.Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.Chem Biol Drug Des2015;86:1036-48 PMCID:PMC4846425

[23] Rowinsky EK,Berdeja JG.Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.Invest New Drugs2020;38:1448-53 PMCID:PMC7497669

[24] Perego P,Righetti SC.Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.Cancer Res1996;56:556-62

[25] Cossa G,Cassinelli G.Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells.Cancer Lett2014;347:212-24

[26] Lee BH,King RW.A high-throughput screening method for identification of inhibitors of the deubiquitinating enzyme USP14.Curr Protoc Chem Biol2012;4:311-30 PMCID:PMC3690187

[27] Friesner RA,Murphy RB.Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.J Med Chem2004;47:1739-49

[28] Corso G, Stärk H, Jing B, Barzilay R, Jaakkola T. DiffDock: diffusion steps, twists, and turns for molecular docking. arXiv. 2023;arXiv:2210.01776. Available from https://doi.org/10.48550/arXiv.2210.01776 [accessed 18 September 2025].

[29] Wang F,Yu B.USP14: structure, function, and target inhibition.Front Pharmacol2021;12:801328 PMCID:PMC8766727

[30] Wang Y,Ding S.Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade.Cell Res2018;28:1186-94 PMCID:PMC6274642

[31] Abraham MJ,Schulz R.GROMACS: high performance molecular simulations through multilevel parallelism from laptops to supercomputers.SoftwareX2015;1-2:19-25

[32] Bouysset C.ProLIF: a library to encode molecular interactions as fingerprints.J Cheminform2021;13:72 PMCID:PMC8466659

[33] Tian C,Belfon KAA.ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution.J Chem Theory Comput2020;16:528-52

[34] der Spoel D, van Maaren PJ. The origin of layer structure artifacts in simulations of liquid water.J Chem Theory Comput2006;2:1-11

[35] Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian-09. Gaussian, Inc.: 340 Quinnipiac St Bldg 40, Wallingford, CT 06492, USA. Available from https://gaussian.com/g09citation [accessed 18 September 2025].

[36] Wang J,Kollman PA.Automatic atom type and bond type perception in molecular mechanical calculations.J Mol Graph Model2006;25:247-60

[37] Wang J,Caldwell JW,Case DA.Development and testing of a general amber force field.J Comput Chem2004;25:1157-74

[38] He X,Yang W,Wang J.A fast and high-quality charge model for the next generation general AMBER force field.J Chem Phys2020;153:114502 PMCID:PMC7728379

[39] Jo S,Iyer VG.CHARMM-GUI: a web-based graphical user interface for CHARMM.J Comput Chem2008;29:1859-65

[40] Marino D, Achsel T, Lacoux C, Falconi M, Bagni C. Molecular dynamics simulations show how the FMRP Ile304Asn mutation destabilizes the KH2 domain structure and affects its function.J Biomol Struct Dyn2014;32:337-50

[41] Humphrey W,Schulten K.VMD: visual molecular dynamics.J Mol Graph1996;14:33-8, 27

[42] Meng EC,Pettersen EF.UCSF ChimeraX: tools for structure building and analysis.Protein Sci2023;32:e4792 PMCID:PMC10588335

[43] Corno C,Arrighetti N.Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.Biochem Pharmacol2017;136:40-50

[44] Lee BH,Park S.Enhancement of proteasome activity by a small-molecule inhibitor of USP14.Nature2010;467:179-84 PMCID:PMC2939003

[45] Di Fruscia P,Bottegoni G.Discovery and SAR evolution of pyrazole azabicyclo[3.2.1]octane sulfonamides as a novel class of non-covalent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitors for oral administration.J Med Chem2021;64:13327-55 PMCID:PMC8474119

[46] Wang Y,Zhong J.Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer.Med Oncol2015;32:379

[47] Shen J,Chen L.Ubiquitin-specific protease 14 regulates ovarian cancer cisplatin-resistance by stabilizing BCL6 oncoprotein.Biochem Biophys Res Commun2020;524:683-8

[48] Boselli M,Robert J.An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons.J Biol Chem2017;292:19209-25 PMCID:PMC5702663

[49] Adelakun N,Adeniyi A,Obaseki E.Discovery of new promising USP14 inhibitors: computational evaluation of the thumb-palm pocket.J Biomol Struct Dyn2022;40:3060-70